PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Cash & equivalents declining -3.88% while TRVN's grows 14.51%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Below half of TRVN's -18.44%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Other current assets growth < half of TRVN's -58.32%. David Dodd sees a leaner approach to short-term items.
-4.12%
Below half of TRVN's -23.74%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-3.46%
1.25-1.5x TRVN's -3.00%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of TRVN's 100.00%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-3.14%
0.5-0.75x TRVN's -5.99%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Below half of TRVN's -21.27%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.45%
Less than half of TRVN's -47.92%. David Dodd sees a more disciplined AP approach or lower volume.
25.40%
Less than half of TRVN's -79.26%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
Below half of TRVN's 100.00%. Michael Burry suspects a big gap in pre-sales traction.
-25.40%
Less than half of TRVN's 100.00%. David Dodd sees fewer expansions in other current obligations.
32.92%
Less than half of TRVN's -2.65%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of TRVN's 2.83%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.45%
Above 1.5x TRVN's 1.03%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
1.25-1.5x TRVN's -2.91%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
Below half TRVN's -39.17%. Michael Burry sees potential underperformance in building shareholder capital.
-4.09%
Below half TRVN's -21.27%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
Above 1.5x TRVN's -0.55%. Michael Burry sees a major jump. Investigate leverage rationale.
3.93%
Less than half of TRVN's -491.51%. David Dodd sees better deleveraging or stronger cash buildup than competitor.